Printer Friendly

SCIOS-NOVA SENIOR SCIENTIST JOINS MACRONEX AS DIRECTOR OF CHEMISTRY

 RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire/ -- Macronex, Inc. today announced it has appointed Bradley J. Benson, Ph.D., as director of chemistry. He will have responsibility for both Macronex's protein and peptide chemistry and medicinal chemistry groups. Dr. Benson brings to the company more than 15 years of experience in biochemistry and the biotechnology industry.
 "Dr. Benson is a tremendous asset to our team at Macronex. He brings to us experience in both the development of protein and peptide therapeutics and in the development of therapeutics for treatment of lung diseases," said George Cianciolo, Ph.D., Macronex's vice president of research and development. "His experience will facilitate the rapid development of several of Macronex's lead compounds, especially those which are targeted for the treatment of lung disorders."
 Prior to joining Macronex, Dr. Benson, 46, was director of protein chemistry at Scios-Nova (NASDAQ: SCIO), a biopharmaceutical company in Mountain View, Calif. He also spent 12 years as a staff member of the Cardiovascular Research Institute of the University of California, San Francisco (UCSF). Dr. Benson was also an assistant professor of biochemistry at UCSF and a consultant for the National Institutes of Health.
 "I am extremely excited about joining Macronex because it is a young, exciting company with unique, proprietary technology and screening which focuses on immune modulation in major disease entities associated with inflammation and immunosuppression," said Dr. Benson.
 Dr. Benson earned a Ph.D. in biochemistry from the University of Arizona where he also received an M.S. and B.S. in zoology. He is an inventor on several patents and has authored more than 50 scientific articles.
 Macronex, a biopharmaceutical discovery and development company, based near Research Triangle Park, was founded in 1990 to exploit scientific advances made in the laboratories of its Duke University Medical Center-based founders. The company is developing therapeutics for acute and chronic inflammatory and autoimmune diseases.
 -0- 1/29/93
 /CONTACT: George Cianciolo, Ph.D., executive vice president - research and development of Macronex, 919-481-4390; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, in New York, 212-979-9180, for Macronex/


CO: Macronex, Inc. ST: North Carolina IN: MTC SU: PER

GK-OS -- NY013 -- 0637 01/29/93 09:34 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 29, 1993
Words:368
Previous Article:THE BANK OF NEW YORK TO ACQUIRE NATIONAL COMMUNITY BANKS
Next Article:ILLINOIS POWER COMPANY SELECTS SYNERCOM WORK MANAGEMENT SOLUTION
Topics:


Related Articles
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION BEGIN DISTRIBUTION OF PROXY STATEMENT TO STOCKHOLDERS
SCIOS NOVA INC. REACQUIRES RIGHTS TO RECOMBINANT HUMAN LUNG SURFACTANT
SCIOS NOVA INC. ANNOUNCES SALE OF NOVASCREEN BUSINESS
SCIOS NOVA ANNOUNCES 1993 FIRST QUARTER FINANCIAL RESULTS
MACRONEX APPOINTS TWO NEW MEMBERS TO SCIENTIFIC ADVISORY BOARD
SCIOS NOVA ANNOUNCES 1993 SECOND QUARTER AND SIX-MONTH FINANCIAL RESULTS
SCIOS NOVA ANNOUNCES REDUCTION IN STAFF AS PART OF REFOCUSED STRATEGIC PLAN
SCIOS NOVA CONSOLIDATES ITS RESEARCH AND DEVELOPMENT OPERATIONS
SCIOS NOVA RECEIVES U.S. PATENT FOR FIBLAST(TM) TROFERMIN (bFGF)
Chiron and Scios Announce Completion of Agreement on Human Basic Fibroblast Growth Factor.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters